Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

c-Cbl targets PD-1 in immune cells for proteasomal degradation and modulates colorectal tumor growth
Chimera Lyle, Sean Richards, Kei Yasuda, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 58

Showing 1-25 of 58 citing articles:

E3 ubiquitin ligases: styles, structures and functions
Quan Yang, Jinyao Zhao, Dan Chen, et al.
Molecular Biomedicine (2021) Vol. 2, Iss. 1
Open Access | Times Cited: 220
Post-translational Modification of PD-1: Potential Targets for Cancer Immunotherapy
Te-An Lee, En-Yun Tsai, Shou-Hou Liu, et al.
Cancer Research (2024) Vol. 84, Iss. 6, pp. 800-807
Open Access | Times Cited: 18
UFL1 ablation in T cells suppresses PD-1 UFMylation to enhance anti-tumor immunity
Chuan He, Xixin Xing, Hsin-Yi Chen, et al.
Molecular Cell (2024) Vol. 84, Iss. 6, pp. 1120-1138.e8
Open Access | Times Cited: 18
PD-1 regulation in immune homeostasis and immunotherapy
Minling Gao, Jie Shi, Xiangling Xiao, et al.
Cancer Letters (2024) Vol. 588, pp. 216726-216726
Closed Access | Times Cited: 18
Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy
Xiaoli Hu, Jing Wang, Man Chu, et al.
Molecular Therapy (2021) Vol. 29, Iss. 3, pp. 908-919
Open Access | Times Cited: 98
Targeting ubiquitin signaling for cancer immunotherapy
Xiaofei Zhou, Shao‐Cong Sun
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 60
Targeting the ubiquitination/deubiquitination process to regulate immune checkpoint pathways
Jiaxin Liu, Yicheng Cheng, Ming Zheng, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 57
ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy
Xiangling Xiao, Jie Shi, Chuan He, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 35
E3 ligase ligand optimization of Clinical PROTACs
Hanrui Jiang, Huan Xiong, Shuang-Xi Gu, et al.
Frontiers in Chemistry (2023) Vol. 11
Open Access | Times Cited: 26
The E3 ubiquitin ligases regulate PD-1/PD-L1 protein levels in tumor microenvironment to improve immunotherapy
Bo Hou, Ting Chen, He Zhang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 26
Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways
Rong Wang, Shiwei He, Jun Long, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 10
Post-translational regulations of PD-L1 and PD-1: Mechanisms and opportunities for combined immunotherapy
Xiaoming Dai, Yang Gao, Wenyi Wei
Seminars in Cancer Biology (2021) Vol. 85, pp. 246-252
Open Access | Times Cited: 53
Tryptophan metabolites suppress the Wnt pathway and promote adverse limb events in chronic kidney disease
Nkiruka Arinze, Wenqing Yin, Saran Lotfollahzadeh, et al.
Journal of Clinical Investigation (2021) Vol. 132, Iss. 1
Open Access | Times Cited: 45
Proteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation
Camilla Ruffilli, Sascha Röth, Mónica Rodrigo, et al.
ACS Pharmacology & Translational Science (2022) Vol. 5, Iss. 10, pp. 849-858
Open Access | Times Cited: 31
PD-1/PD-L1 axis in organ fibrosis
Youliang Zhao, Yaqian Qu, Changfu Hao, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 21
E3 ubiquitin ligases in cancer stem cells: key regulators of cancer hallmarks and novel therapeutic opportunities
Qiang Zou, Meng Liu, Kewei Liu, et al.
Cellular Oncology (2023) Vol. 46, Iss. 3, pp. 545-570
Open Access | Times Cited: 17
Role of the ubiquitin–proteasome system on macrophages in the tumor microenvironment
Yue Xiao, Ruiqian Liu, Na Li, et al.
Journal of Cellular Physiology (2024) Vol. 239, Iss. 2
Closed Access | Times Cited: 6
CREG1 deficiency impaired myoblast differentiation and skeletal muscle regeneration
Haixu Song, Xiaoxiang Tian, Lianqi He, et al.
Journal of Cachexia Sarcopenia and Muscle (2024) Vol. 15, Iss. 2, pp. 587-602
Open Access | Times Cited: 6
Metformin Suppresses Both PD-L1 Expression in Cancer Cells and Cancer-Induced PD-1 Expression in Immune Cells to Promote Antitumor Immunity
Su Hwan Park, J.H. Lee, Hye Jin Yun, et al.
Annals of Laboratory Medicine (2024) Vol. 44, Iss. 5, pp. 426-436
Open Access | Times Cited: 6
PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy
Xiaohui Ren, Lijuan Wang, Likun Liu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Ubiquitination in T-Cell Activation and Checkpoint Inhibition: New Avenues for Targeted Cancer Immunotherapy
Shubhangi Gavali, Jianing Liu, Xinyi Li, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 19, pp. 10800-10800
Open Access | Times Cited: 37
The depths of PD-1 function within the tumor microenvironment beyond CD8+ T cells
Stephanie Laba, Grace Mallett, Shoba Amarnath
Seminars in Cancer Biology (2021) Vol. 86, pp. 1045-1055
Open Access | Times Cited: 33
How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC
Li Chen, Xiaoying Jiang, Yuanheng Li, et al.
Clinical Immunology (2022) Vol. 237, pp. 108962-108962
Closed Access | Times Cited: 27
Anti‐tumour potential of PD‐L1 / PD ‐1 post‐translational modifications
Shimeng Zhou, Jinfeng Zhu, Jingwei Xu, et al.
Immunology (2022) Vol. 167, Iss. 4, pp. 471-481
Open Access | Times Cited: 24
Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy
Xian-Miao Li, Zhenyu Zhao, Yu Xiao, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top